Gain Therapeutics, Inc. develops allosteric small molecule therapies for neurodegenerative and other difficult-to-treat diseases. The company’s lead candidate, GT-02287, is being developed for Parkinson’s disease with or without a GBA1 mutation and is designed as a brain-penetrant allosteric enzyme modulator of glucocerebrosidase, or GCase.
Recurring news for GANX includes financial results, corporate updates, clinical and biomarker data for GT-02287, FDA and IND-related communications, and scientific presentations at Parkinson’s and neurodegeneration conferences. Company updates also cover the Magellan™ drug discovery platform, preclinical GCase modulator programs such as GT-04686, and pipeline areas including lysosomal storage disorders, metabolic diseases and solid tumors.
Gain Therapeutics has presented data at the Federation of European Neuroscience Societies (FENS) Forum 2024 showing that their lead therapeutic candidate, GT-02287, has significantly improved cognitive function and activities of daily living in a preclinical model of GBA1 Parkinson's disease (GBA1-PD). The study demonstrated a reversal of motor function deficits in mice, assessed through nest-building and motor performance tests. The GT-02287 therapy was administered orally and showed promising results in enhancing daily activities reflecting human cognitive performance. The presentation, made on June 27, 2024, aligns with the company’s ongoing Phase 1 clinical study aimed at delivering effective treatments for Parkinson’s disease.
Gain Therapeutics, a clinical-stage biotechnology company, announced that its CFO, Gene Mack, will participate in H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024. The event will feature a fireside chat and virtual one-on-one meetings. Attendees can watch the fireside chat starting at 7:00am ET through an on-demand webcast. A replay will be available on Gain Therapeutics' website under the Investors and Media section following the event. Gain Therapeutics is recognized for its work in developing allosteric small molecule therapies.
Gain Therapeutics announced the pricing of an $11.0 million public offering, consisting of 7,116,547 common shares at $1.35 per share and pre-funded warrants for 1,031,602 shares. The pre-funded warrants are exercisable immediately. Gain has also given the underwriter a 30-day option to purchase an additional 1,222,222 common shares. Titan Partners Group is the sole bookrunner. The offering is set to close around June 17, 2024, pending customary conditions. The proceeds will support clinical and nonclinical development of GT-02287 for neurodegenerative diseases and other corporate purposes. The securities are being offered via a prospectus supplement, which is available on the SEC's website.
Gain Therapeutics, a Nasdaq-listed company (GANX), announced a public offering of its common stock and pre-funded warrants. The offering's final terms will depend on market conditions. Gain plans to use the proceeds to further develop its lead candidate, GT-02287, aimed at treating neurodegenerative diseases like GBA1 Parkinson's disease, and for general corporate purposes. Titan Partners Group is the sole bookrunner for this offering. All securities will be offered by Gain under a previously filed shelf registration statement with the SEC.
Gain Therapeutics has announced that its late-breaking abstract on GT-02287, a clinical-stage GCase enhancer, has been accepted for presentation at the FENS Forum 2024 in Vienna. New data reveals improvements in cognitive performance in a preclinical model of GBA1 Parkinson’s disease. The presentation is scheduled for June 27, 2024, and will be delivered by Dr. Beatriz Calvo-Flores Guzman. The FENS Forum is Europe's largest neuroscience congress, encompassing both basic and translational research. This recognition could potentially highlight the innovative strides Gain Therapeutics is making in the biotechnology sector, particularly in treating neurodegenerative diseases.
Gain Therapeutics (Nasdaq: GANX) has released its Q1 2024 financial results, reporting positive developments despite a decrease in both R&D and G&A expenses. The company announced favorable outcomes from the SAD part of its Phase 1 GT-02287 trial, initiated the MAD portion, and presented promising data on neuroprotection in Parkinson’s models.
Key executive appointments were made, with Gene Mack as CFO and Jonas Hannestad as CMO. The company maintains a cash runway into 2025, supported by potential grant applications. Financially, R&D expenses decreased by $0.3M to $2.5M, and G&A expenses fell by $0.6M to $1.9M. Net loss per share improved to $0.22 from $0.43 YoY. Cash reserves dropped to $12.7M from $16.8M year-end 2023.
Summary not available.
Summary not available.
Summary not available.
Summary not available.